![]() Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. LGND beat earnings estimates in one of the last four reported quarters. Ligand’s earnings per share estimates for 2023 increased to $4.32 from $3.30 in the past 30 days. In the past 30 days, estimates for Novo Nordisk’s 2023 earnings per share have risen from $4.20 to $4.43 and the same for 2024 had moved up 29 cents to $5.19. You can see the complete list of today’s Zacks #1 Rank stocks here. Both sport a Zacks Rank #1 (Strong Buy) at present. ![]() Some better-ranked stocks in the overall healthcare sector are Novo Nordisk NVO and Ligand Therapeutics LGND. Gilead currently carries a Zacks Rank #3 (Hold). Strong patient demand for the new HIV medicines (Dovato, Cabenuva, Juluca, Rukobia and Apretude) boosted GSK’s HIV franchise in 2022. However, competition from the likes of GSK plc GSK is stiff. Hence, Gilead should put up an exemplary performance in 2023 on the back of its legacy HIV business and the strong uptake of its oncology business. Trodelvy sales increased 79% in 2022 from 2021, reflecting continued adoption in metastatic triple-negative breast cancer (“TNBC”) in the United States and Europe. The uptake of the breast cancer drug Trodelvy has been strong in 2022. The Cell Therapy franchise comprising Yescarta and Tecartus sales increased 68% to $1.5 billion in 2022 from 2021 primarily due to higher demand for Yescarta in R/R LBCL, as well as Tecartus in R/R ALL and MCL. The oncology business put up a stellar performance in 2022 and fueled the top line. ![]() Hence, sales in 2023 are expected to get a boost from incremental Sunlenca revenues. It was also approved by the European Commission. In addition, Sunlenca is the only HIV treatment option administered twice a year, acting as a big advantage over the existing treatments and enabling Gilead to capture market share. ![]() Sunlenca is designed to inhibit HIV at multiple stages of its lifecycle and has no known cross-resistance to other existing drug classes. Most antivirals act on just one stage of viral replication. Sales from this franchise were $17.2 billion in 2022, up 5% from 2021.Īdditionally, Gilead’s HIV franchise got a boost with the FDA’s approval of lenacapavir under the brand name Sunlenca in combination with other antiretroviral(s) for the treatment of HIV-1 infection in heavily treatment-experienced (HTE) adults with multi-drug-resistant (MDR) HIV-1 infection. Biktarvy remains the leading treatment for those seeking to switch to a new regimen in the United States, as well as those starting treatments in both the United States and Europe. by user and they confirmed that they have the permission to share it. Gilead has a strong HIV portfolio with Biktarvy and Descovy. Trading price action trends : technical analysis of price charts bar by bar for. ![]()
0 Comments
Leave a Reply. |